ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application

Introduction: There exist controversies on recurrence and aggressiveness after use of first-line bevacizumab (BEV) which has been approved in Japan and proven to be beneficial. Therefore, we analyzed the clinical impact of BEV approval by investigating the overall clinical course and glioblastoma (G...

Descripción completa

Detalles Bibliográficos
Autores principales: Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699102/
http://dx.doi.org/10.1093/noajnl/vdaa143.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699102/
http://dx.doi.org/10.1093/noajnl/vdaa143.032

Ejemplares similares